The second phase of the ADVANTAGE AF study of the FARAPULSE™ Pulsed Field Ablation System successfully meets primary safety and efficacy endpoints
Boston Scientific Corporation announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT™ PFA Catheter in patients with persistent atrial fibrillation (AF). Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in Circulation.